197 related articles for article (PubMed ID: 35267606)
1. Monocarboxylate Transporters Are Involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma.
Ufuk A; Garner T; Stevens A; Latif A
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267606
[TBL] [Abstract][Full Text] [Related]
2. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
3. Desmoplasia of pancreatic ductal adenocarcinoma.
Pandol S; Edderkaoui M; Gukovsky I; Lugea A; Gukovskaya A
Clin Gastroenterol Hepatol; 2009 Nov; 7(11 Suppl):S44-7. PubMed ID: 19896098
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities.
Myo Min KK; Ffrench CB; Jessup CF; Shepherdson M; Barreto SG; Bonder CS
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190281
[TBL] [Abstract][Full Text] [Related]
5. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
[TBL] [Abstract][Full Text] [Related]
6. UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy.
Liao X; Huang R; Wang X; Huang K; Yang C; Zhou X; Han C; Su H; Ye X; Liu K; Zhu G; Peng T
J Cancer; 2021; 12(7):2122-2139. PubMed ID: 33754011
[No Abstract] [Full Text] [Related]
7. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential.
Cannon A; Thompson C; Hall BR; Jain M; Kumar S; Batra SK
Genes Cancer; 2018 Mar; 9(3-4):78-86. PubMed ID: 30108679
[TBL] [Abstract][Full Text] [Related]
8. Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues.
Atay S
PeerJ; 2020; 8():e10141. PubMed ID: 33194391
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation.
Li L; Bao J; Wang H; Lei JH; Peng C; Zeng J; Hao W; Zhang X; Xu X; Yu C; Deng CX; Chen Q
Theranostics; 2021; 11(4):1672-1689. PubMed ID: 33408774
[No Abstract] [Full Text] [Related]
10. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
11. Autoregulation of H
Blaszczak W; Williams H; Swietach P
Br J Cancer; 2022 Oct; 127(7):1365-1377. PubMed ID: 35840734
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of ASPM, BUB1B and SPDL1 in tumor tissues predicts poor survival in patients with pancreatic ductal adenocarcinoma.
Tian X; Wang N
Oncol Lett; 2020 Apr; 19(4):3307-3315. PubMed ID: 32218868
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
14. Targeting Pancreatic Stellate Cells in Cancer.
Schnittert J; Bansal R; Prakash J
Trends Cancer; 2019 Feb; 5(2):128-142. PubMed ID: 30755305
[TBL] [Abstract][Full Text] [Related]
15. Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression.
Pan Z; Li L; Fang Q; Zhang Y; Hu X; Qian Y; Huang P
Cancer Cell Int; 2018; 18():214. PubMed ID: 30598639
[TBL] [Abstract][Full Text] [Related]
16. Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method.
Lin Y; Jin Y; Lin LJ; Cao Y; Zhang Y; Chen SF; Zheng CQ
Gene; 2014 May; 540(2):232-7. PubMed ID: 24561286
[TBL] [Abstract][Full Text] [Related]
17. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
[TBL] [Abstract][Full Text] [Related]
18. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma.
Sato N; Cheng XB; Kohi S; Koga A; Hirata K
Acta Pharm Sin B; 2016 Mar; 6(2):101-5. PubMed ID: 27006892
[TBL] [Abstract][Full Text] [Related]
19. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.
Kong SC; Nøhr-Nielsen A; Zeeberg K; Reshkin SJ; Hoffmann EK; Novak I; Pedersen SF
Pancreas; 2016 Aug; 45(7):1036-47. PubMed ID: 26765963
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis.
Yun Z; Meng F; Li S; Zhang P
Aging (Albany NY); 2021 Feb; 13(4):6041-6054. PubMed ID: 33581689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
